Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
08 Aug 2024
Historique:
received: 04 12 2023
accepted: 31 07 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: epublish

Résumé

Haematology patients with high-risk neutropenia are prone to mucosal-barrier injury-associated laboratory-confirmed bloodstream infections (MBI-LCBI). We assessed risk factors for MBI-LCBI including candidaemia in neutropenic haematology patients with fever. This prospective observational study was performed in six dedicated haematology units in the Netherlands. Eligible haematology patients had neutropenia < 500/mL for ≥ 7 days and had fever. MBI-LCBIs were classified according to Centers for Disease Control (CDC) definitions and were followed until the end of neutropenia > 500/mL or discharge. We included 416 patients from December 2014 until August 2019. We observed 63 MBI-LCBIs. Neither clinical mucositis scores nor the blood level of citrulline at fever onset was associated with MBI-LCBI. In the multivariable analysis, MASCC-score (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.05 to 1.29 per point decrease), intensive chemotherapy (OR 3·81, 95% CI 2.10 to 6.90) and Pichia kudriavzevii (formerly Candida krusei) colonisation (OR 5.40, 95% CI 1.75 to 16.7) were retained as risk factors for MBI-LCBI, while quinolone use seemed protective (OR 0.42, 95% CI 0.20 to 0.92). Citrulline level (OR 1.57, 95% CI 1.07 to 2.31 per µmol/L decrease), active chronic obstructive pulmonary disease (OR 15.4, 95% CI 1.61 to 14.7) and colonisation with fluconazole-resistant Candida (OR 8.54, 95% CI 1.51 to 48.4) were associated with candidaemia. In haematology patients with fever during neutropenia, hypocitrullinaemia at fever onset was associated with candidaemia, but not with bacterial MBI-LCBI. Patients with intensive chemotherapy with a low MASCC-score and colonisation with Pichia kudriavzevii had the highest risk of MBI-LCBI. ClinicalTrials.gov (NCT02149329) at 19-NOV-2014.

Identifiants

pubmed: 39115709
doi: 10.1007/s00520-024-08776-w
pii: 10.1007/s00520-024-08776-w
doi:

Banques de données

ClinicalTrials.gov
['NCT02149329']

Types de publication

Journal Article Observational Study Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

579

Subventions

Organisme : ZonMw
ID : 836011030
Pays : Netherlands
Organisme : ZonMw
ID : 836011030
Pays : Netherlands
Organisme : Fonds NutsOhra
ID : 1302-002
Organisme : Fonds NutsOhra
ID : 1302-002

Informations de copyright

© 2024. The Author(s).

Références

Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32–S37
doi: 10.1086/383050 pubmed: 15250018
Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4(4):277–284
doi: 10.1038/nrc1318 pubmed: 15057287
Herbers AH, Blijlevens NM, Donnelly JP, de Witte TJ (2008) Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. Bone Marrow Transplant 42(5):345–349
doi: 10.1038/bmt.2008.170 pubmed: 18587437
Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM (2014) Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl Infect Dis 16(2):279–285
doi: 10.1111/tid.12195 pubmed: 24621081
van der Velden WJ, Herbers AH, Netea MG, Blijlevens NM (2014) Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol 167(4):441–452
doi: 10.1111/bjh.13113 pubmed: 25196917
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52(4):e56-93
doi: 10.1093/cid/cir073 pubmed: 21258094
Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 98(12):1826–35 https://doi.org/10.3324/haematol.2013.091025
Facchini L, Martino R, Ferrari A, Pinana JL, Valcarcel D, Barba P et al (2012) Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. Eur J Haematol 88(1):46–51
doi: 10.1111/j.1600-0609.2011.01724.x pubmed: 22023368
de Mooij CEM, van der Velden W, de Haan AFJ, Fazel S, van Groningen LFJ, Blijlevens NMA (2022) Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy. Bone Marrow Transplant 57(9):1373–1381
doi: 10.1038/s41409-022-01719-1 pubmed: 35661156
De Pietri S, Weischendorff S, Rathe M, Frandsen TL, Hasle H, Nersting J, et al. Gastrointestinal barrier integrity and mucosal inflammation as risk factors of blood stream infections in children treated for acute lymphoblastic leukaemia. Int J Cancer. 2023. https://doi.org/10.1002/ijc.34639
Weischendorff S, Rathe M, Petersen MJ, Weimann A, Enevold C, Nielsen CH, et al. Markers of intestinal mucositis to predict blood stream infections at the onset of fever during treatment for childhood acute leukemia. Leukemia. 2023. https://doi.org/10.1038/s41375-023-02077-7
Dandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V et al (2020) Incidence, risk factors, and outcomes of patients who develop mucosal barrier injury-laboratory confirmed bloodstream infections in the first 100 days after allogeneic hematopoietic stem cell transplant. JAMA Netw Open 3(1):e1918668
doi: 10.1001/jamanetworkopen.2019.18668 pubmed: 31913492 pmcid: 6991246
Stoma I, Littmann ER, Peled JU, Giralt S, van den Brink MRM, Pamer EG, Taur Y (2021) Compositional flux within the intestinal microbiota and risk for bloodstream infection with gram-negative bacteria. Clin Infect Dis 73(11):e4627–e4635
doi: 10.1093/cid/ciaa068 pubmed: 31976518
Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1(1):CD004386. https://doi.org/10.1002/14651858.CD004386.pub3
de Jonge NA, Sikkens JJ, Zweegman S, Beeker A, Ypma P, Herbers AH et al (2022) Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Lancet Haematol 9(8):e563–e572
doi: 10.1016/S2352-3026(22)00145-4 pubmed: 35691326
McAnena OJ, Moore FA, Moore EE, Jones TN, Parsons P (1991) Selective uptake of glutamine in the gastrointestinal tract: confirmation in a human study. Br J Surg 78(4):480–482
doi: 10.1002/bjs.1800780429 pubmed: 1903318
van der Velden WJ, Herbers AH, Bruggemann RJ, Feuth T, Peter Donnelly J, Blijlevens NM (2013) Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. Bone Marrow Transplant 48(7):977–981
doi: 10.1038/bmt.2012.278 pubmed: 23334276
Demacker PN, Beijers AM, van Daal H, Donnelly JP, Blijlevens NM, van den Ouweland JM (2009) Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. J Chromatogr B Analyt Technol Biomed Life Sci 877(4):387–392
doi: 10.1016/j.jchromb.2008.12.041 pubmed: 19144577
National Healthcare Safety Network (NHSN) (2023) Patient Safety Component Manual. Chapter 4: Bloodstream infection event (central line-associated bloodstream infection and non-central line associated bloodstream infection) https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf
World Health Organization (1979) WHO Offset Publication. p. 15–22
Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 November 27. 2017
Satheeshkumar PS, Blijlevens N, Sonis ST (2023) Application of big data analyses to compare the impact of oral and gastrointestinal mucositis on risks and outcomes of febrile neutropenia and septicemia among patients hospitalized for the treatment of leukemia or multiple myeloma. Support Care Cancer 31(3):199
doi: 10.1007/s00520-023-07654-1 pubmed: 36869162
Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M et al (2011) Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 19(7):1001–1008
doi: 10.1007/s00520-010-0925-7 pubmed: 20596732
Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555–560
doi: 10.1007/s00520-004-0614-5 pubmed: 15197637
van Vliet MJ, Tissing WJ, Rings EH, Koetse HA, Stellaard F, Kamps WA, de Bont ES (2009) Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 53(7):1188–1194
doi: 10.1002/pbc.22210 pubmed: 19688831
Yeshurun M, Rozovski U, Shargian L, Pasvolsky O, van der Werf S, Tridello G et al (2023) Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant 58(4):414–423
doi: 10.1038/s41409-023-01916-6 pubmed: 36653669

Auteurs

Nick A de Jonge (NA)

Department of Haematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands. ni.dejonge@amsterdamumc.nl.
Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands. ni.dejonge@amsterdamumc.nl.
Department of Haematology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. ni.dejonge@amsterdamumc.nl.

Jeroen J W M Janssen (JJWM)

Department of Haematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
Department of Haematology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands.

Paula Ypma (P)

Department of Haematology, HAGA Hospital, Els-Borst-Eilersplein 275, 2545 AA, The Hague, the Netherlands.

Alexandra H E Herbers (AHE)

Department of Haematology and Oncology, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, Hertogenbosch, Netherlands.

Arne de Kreuk (A)

Department of Internal Medicine, OLVG, Jan Tooropstraat 164, 1061 AE, Amsterdam, the Netherlands.

Wies Vasmel (W)

Department of Internal Medicine, OLVG, Jan Tooropstraat 164, 1061 AE, Amsterdam, the Netherlands.

Jody M W van den Ouweland (JMW)

Department of Clinical Chemistry, Canisius-Wilhelmina Hospital, Weg Door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands.

Aart Beeker (A)

Department of Internal Medicine, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp, the Netherlands.

Otto Visser (O)

Department of Medicine, Isala, Dokter Van Heesweg 2, 8025 AB, Zwolle, the Netherlands.

Sonja Zweegman (S)

Department of Haematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.

Nicole M A Blijlevens (NMA)

Department of Haematology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands.

Michiel A van Agtmael (MA)

Department of Internal Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.

Jonne J Sikkens (JJ)

Department of Internal Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH